Nonleg venous thrombosis in critically ill adults: a nested prospective cohort study.

IMPORTANCE Critically ill patients are at risk of venous thrombosis, and therefore guidelines recommend daily thromboprophylaxis. Deep vein thrombosis (DVT) commonly occurs in the lower extremities but can occur in other sites including the head and neck, trunk, and upper extremities. The risk of nonleg deep venous thromboses (NLDVTs), predisposing factors, and the association between NLDVTs and pulmonary embolism (PE) or death are unclear. OBJECTIVE To describe the frequency, anatomical location, risk factors, management, and consequences of NLDVTs in a large cohort of medical-surgical critically ill adults. DESIGN, SETTING, AND PARTICIPANTS A nested prospective cohort study in the setting of secondary and tertiary care intensive care units (ICUs). The study population comprised 3746 patients, who were expected to remain in the ICU for at least 3 days and were enrolled in a randomized clinical trial of dalteparin vs standard heparin for thromboprophylaxis. MAIN OUTCOMES AND MEASURES The proportion of patients who had NLDVTs, the mean number per patient, and the anatomical location. We characterized NLDVTs as prevalent or incident (identified within 72 hours of ICU admission or thereafter) and whether they were catheter related or not. We used multivariable regression models to evaluate risk factors for NLDVT and to examine subsequent anticoagulant therapy, associated PE, and death. RESULTS Of 3746 trial patients, 84 (2.2%) developed 1 or more non-leg vein thromboses (superficial or deep, proximal or distal). Thromboses were more commonly incident (n = 75 [2.0%]) than prevalent (n = 9 [0.2%]) (P < .001) and more often deep (n = 67 [1.8%]) than superficial (n = 31 [0.8%]) (P < .001). Cancer was the only independent predictor of incident NLDVT (hazard ratio [HR], 2.22; 95% CI, 1.06-4.65). After adjusting for Acute Physiology and Chronic Health Evaluation (APACHE) II scores, personal or family history of venous thromboembolism, body mass index, vasopressor use, type of thromboprophylaxis, and presence of leg DVT, NLDVTs were associated with an increased risk of PE (HR, 11.83; 95% CI, 4.80-29.18). Nonleg DVTs were not associated with ICU mortality (HR, 1.09; 95% CI, 0.62-1.92) in a model adjusting for age, APACHE II, vasopressor use, mechanical ventilation, renal replacement therapy, and platelet count below 50 × 10(9)/L. CONCLUSIONS AND RELEVANCE Despite universal heparin thromboprophylaxis, nonleg thromboses are found in 2.2% of medical-surgical critically ill patients, primarily in deep veins and proximal veins. Patients who have a malignant condition may have a significantly higher risk of developing NLDVT, and patients with NLDVT, compared with those without, appeared to be at higher risk of PE but not higher risk of death. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00182143.

[1]  Michael K Gould,et al.  Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[2]  Elie A Akl,et al.  Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .

[3]  David H. Nguyen,et al.  The natural history of upper extremity deep venous thromboses in critically ill surgical and trauma patients: what is the role of anticoagulation? , 2011, The Journal of trauma.

[4]  C. Mai,et al.  Upper-extremity deep venous thrombosis: a review. , 2011, The American journal of medicine.

[5]  G. Guyatt,et al.  Dalteparin versus unfractionated heparin in critically ill patients. , 2011, The New England journal of medicine.

[6]  G. Guyatt,et al.  PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan. , 2011, Journal of critical care.

[7]  N. Kucher Clinical practice. Deep-vein thrombosis of the upper extremities. , 2011, The New England journal of medicine.

[8]  P. Libby,et al.  A randomized trial of rosuvastatin in the prevention of venous thromboembolism. , 2009, The New England journal of medicine.

[9]  Jianmin Tian,et al.  Acute kidney injury criteria predict outcomes of critically ill patients* , 2008, Critical care medicine.

[10]  M. Guil,et al.  Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. , 2008, Chest.

[11]  François Vincent,et al.  Platelet count decline: an early prognostic marker in critically ill patients with prolonged ICU stays. , 2007, Chest.

[12]  R. Goldberg,et al.  Upper extremity deep vein thrombosis: a community-based perspective. , 2007, The American journal of medicine.

[13]  G. Moneta Upper-Extremity Deep Vein Thrombosis: A Prospective Registry of 592 Patients , 2006 .

[14]  John A Kellum,et al.  Acute renal failure in critically ill patients: a multinational, multicenter study. , 2005, JAMA.

[15]  Michael A Babyak,et al.  What You See May Not Be What You Get: A Brief, Nontechnical Introduction to Overfitting in Regression-Type Models , 2004, Psychosomatic medicine.

[16]  J. le Gall,et al.  Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients* , 2002, Critical care medicine.

[17]  J. Vincent,et al.  Time course of platelet counts in critically ill patients , 2002, Critical care medicine.

[18]  M. Kollef,et al.  Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis , 2002, Critical care medicine.

[19]  A. Wilmer,et al.  Thrombocytopenia and prognosis in intensive care , 2000, Critical care medicine.

[20]  P Prandoni,et al.  Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. , 1997, Archives of internal medicine.

[21]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.